Pear Therapeutics, Inc. Warrant
PEARW
PEARW was delisted on the 18th of April, 2023.
33 hedge funds and large institutions have $3.57M invested in Pear Therapeutics, Inc. Warrant in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
8% less funds holding
Funds holding: 36 → 33 (-3)
38% less capital invested
Capital invested by funds: $5.76M → $3.57M (-$2.19M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$89K |
| 2 |
DCM
Difesa Capital Management
New York
|
+$24K |
| 3 |
Jane Street
New York
|
+$52 |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$30 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$13K |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$3K |
| 3 |
SG
StoneX Group
New York
|
-$1.7K |
| 4 |
AR
Advisory Research
Chicago,
Illinois
|
-$799 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$627 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FTUS
26
Flow Traders U.S.
New York
| $2K | +$30 | +186 | +1% |
|
|
BCM
27
BCK Capital Management
Stamford,
Connecticut
| $1.9K | – | – | – |
|
28
Walleye Trading
New York
| $1.58K | – | – | – |
|
|
VI
29
Vestcor Inc
Fredericton,
New Brunswick, Canada
| $1K | – | – | – |
|
|
30
UBS Group
Zurich,
Switzerland
| $375 | -$627 | -3,921 | -61% |
|
|
WTA
31
Washington Trust Advisors
Wellesley,
Massachusetts
| $149 | – | – | – |
|
32
Morgan Stanley
New York
| $110 | – | – | – |
|
|
33
Citadel Advisors
Miami,
Florida
| – | -$13K | -75,414 | Closed |
|
|
OMC
34
Old Mission Capital
Chicago,
Illinois
| – | -$3K | -17,563 | Closed |
|
|
SG
35
StoneX Group
New York
| – | -$1.7K | -10,000 | Closed |
|
PEARW Hedge Fund Activity: Q4 2022 in Review
33 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Warrant (PEARW) for Q4 2022, worth a combined $3.57M — down 38% from $5.76M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PEARW and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Walleye Capital, adding an estimated $89K. The largest seller was Citadel Advisors, exiting entirely with an estimated $13K sold.
- 33 institutional investors held Pear Therapeutics, Inc. Warrant (PEARW) as of Q4 2022, down from 36 in Q3 2022.
- Funds reported $3.57M of Pear Therapeutics, Inc. Warrant stock for Q4 2022, down 38% quarter-over-quarter.
- 0 funds opened new Pear Therapeutics, Inc. Warrant positions in Q4 2022 and 3 closed out, a net change of -3 holders.
- The largest Pear Therapeutics, Inc. Warrant buyer in Q4 2022 was Walleye Capital, an estimated $89K added.
- The largest Pear Therapeutics, Inc. Warrant seller in Q4 2022 was Citadel Advisors, an estimated $13K sold.
Based on aggregated 13F filings for Q4 2022.